Clusterin (CLU) and lung cancer

Advances in Cancer Research

Volumn 105, Issue , 2009, Pages 63-76

  Panico, F ^a   Rizzi, F ^b,c   Fabbri, L M ^a   Bettuzzi, Saverio ^b,c   Luppi, F ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLU PROTEIN, HUMAN; CLUSTERIN; SMALL INTERFERING RNA;

DISEASE COURSE; DRUG ANTAGONISM; GENETICS; HUMAN; LUNG TUMOR; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW;

CLUSTERIN; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; RNA, SMALL INTERFERING;

EID: 73949083156     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(09)05004-0     Document Type: Review

References (59)

1. Albert, J. M., et al. (2007). Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol. Biomarkers Prev. 16, 1845-1851.
2. Avital, I., et al. (2007). Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 25, 2903-2909.
3. Bettuzzi, S., et al. (2002). Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 21, 4328-4334.
4. Borczuk, A. C., et al. (2009). Genomics of lung cancer. Proc. Am. Thorac. Soc. 6, 152-158.
5. 2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ. 12, 101-104.
6. Cai, L., et al. (2005). Effects of navelbine and docetaxel on gene expression in lung cancer cell strains. Acta Pharmacol. Sin. 26, 1017-1024.
7. Cao, C., et al. (2005). Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Int. J. Radiat. Oncol. Biol. Phys. 63, 1228-1236.
8. Carnevali, S., et al. (2006). Clusterin decreases oxidative stress in lung fibroblasts exposed to cigarette smoke. Am. J. Respir. Crit. Care Med. 174, 393-399.
9. Carney, D. N., and Hansen, H. H. (2000). Non-small-cell lung cancer-stalemate or progress? N. Engl. J. Med. 343, 1261-1262.
10. Chi, K. N., et al. (2008). A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin. Cancer Res. 14, 833-839.
11. Chou, T. Y., et al. (2009). Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal. 21, 704-711.
12. Criswell, T., et al. (2003). Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol. Ther. 2, 372-380.
13. French, L. E., et al. (1993). Murine clusterin: Molecular cloning and mRNA localization of a gene associated with epithelial differentiation processes during embryogenesis. J. Cell Biol. 122, 1119-1130.
14. Gassler, N., et al. (2001). Expression of clusterin in Crohn's disease of the terminal ileum. Histol. Histopathol. 16, 755-762.
15. Gleave, M., and Miyake, H. (2005). Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J. Urol. 23, 38-46.
16. Guarino, M., et al. (2007). The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39, 305-318.
17. Hara, I., et al. (2001). Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J. Cancer Res. 92, 1220-1224.
18. Hecht, S. S. (2002). Cigarette smoking and lung cancer: Chemical mechanisms and approaches to prevention. Lancet Oncol. 3, 461-469.
19. Heller, A. R., et al. (2003). Clusterin protects the lung from leukocyte-induced injury. Shock 20, 166-170.
20. Houghton, J., et al. (2004). Gastric cancer originating from bone marrow-derived cells. Science 306, 1568-1571.
21. Jemal, A., et al. (2006). Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130.
22. Jemal, A., et al. (2008). Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96.
23. Jonsson, S., et al. (2008). Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Am. J. Respir. Crit. Care Med. 177, 342-347.
24. July, L. V., et al. (2002). Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50, 179-188.
25. July, L. V., et al. (2004). Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 3, 223-232.
26. Lakins, J., et al. (1998). Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J. Biol. Chem. 273, 27887-27895.
27. Lau, S. H., et al. (2006). Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 25, 1242-1250.
28. Leskov, K. S., et al. (2001). When X-ray-inducible proteins meet DNA double strand break repair. Semin. Radiat. Oncol. 11, 352-372.
29. Leskov, K. S., et al. (2003). Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 278, 11590-11600.
30. Maheswaran, S., et al. (2008). Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377.
31. Miyake, H., et al. (2001). Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 7, 4245-4252.
32. Miyake, H., et al. (2003). Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol. Rep. 10, 469-473.
33. Miyake, H., et al. (2004). Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate 61, 318-323.
34. Moretti, R. M., et al. (2007). Clusterin isoforms differentially affect growth and motility of prostate cells: Possible implications in prostate tumorigenesis. Cancer Res. 67, 10325-10333.
35. Niklinski, J., et al. (2001). Prognostic molecular markers in non-small cell lung cancer. Lung Cancer 34(Suppl. 2), S53-S58.
36. Ohe, Y. (2004). Chemoradiotherapy for lung cancer: Current status and perspectives. Int. J. Clin. Oncol. 9, 435-443.
37. Okano, T., et al. (2006). Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 6, 3938-3948.
38. Osada, H., and Takahashi, T. (2002). Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 21, 7421-7434.
39. Paik, S., et al. (2004). A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N. Engl. J. Med. 351, 2817-2826.
40. Powell, C. A. (2008). Waiting to exhale. Am. J. Respir. Crit. Care Med. 177, 246-247.
41. Pucci, S., et al. (2004). Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23, 2298-2304.
42. Raso, M. G., and Wistuba, I. I. (2007). Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers. J. Thorac. Oncol. 2, S128-S135.
43. Redondo, M., et al. (2000). Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 157, 393-399.
44. Rizzi, F., and Bettuzzi, S. (2008). Targeting Clusterin in prostate cancer. J. Physiol. Pharmacol. 59(Suppl. 9), 265-274.
45. Romond, E. H., et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684.
46. Scaltriti, M., et al. (2004a). Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int. J. Cancer 108, 23-30.
47. Scaltriti, M., et al. (2004b). Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1. Cancer Res. 64, 6174-6182.
48. Schwartz, A. G., et al. (2007). The molecular epidemiology of lung cancer. Carcinogenesis 28, 507-518.
49. Shannan, B., et al. (2006). Challenge and promise: Roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 13, 12-19.
50. Smythe, W. R. (2003).Treatment of stage I non-small cell lung carcinoma. Chest 123, 181S-187S.
51. Spitz, M. R., et al. (2003). Genetic susceptibility to lung cancer: The role of DNA damage and repair. Cancer Epidemiol. Biomarkers Prev. 12, 689-698.
52. Trougakos, I. P., and Gonos, E. S. (2002). Clusterin/apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell. Biol. 34, 1430-1448.
53. Vineis, P., et al. (2007). Evidence of gene gene interactions in lung carcinogenesis in a large pooled analysis. Carcinogenesis 28, 1902-1905.
54. Xie, D., et al. (2005). Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. World J. Gastroenterol. 11, 3285-3289.
55. Yang, J., and Weinberg, R. A. (2008). Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell 14, 818-829.
56. Yang, C. R., et al. (1999). Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Res. 27, 2165-2174.
57. Yang, C. R., et al. (2000). Nuclear clusterin/XIP8, an X-ray-induced Ku70-binding protein that signals cell death. Proc. Natl. Acad. Sci. USA 97, 5907-5912.
58. Zellweger, T., et al. (2002). Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin. Cancer Res. 8, 3276-3284.
59. Zellweger, T., et al. (2003). Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int. 92, 463-469.